Baseline characteristics
Characteristic . | MGZL (N = 10) . |
---|---|
Age, y | 35 (25-72) |
>65 | 1∗ (10) |
Male | 6 (60) |
ECOG performance status | |
0-1 | 9 (90) |
≥2 | 1 (10) |
Refractory disease† | 7 (70) |
Bulky disease >10 cm | 3 (30) |
Prior systemic cancer therapies, median (range) | 2 (1-3)‡ |
Prior therapies | 3 (30) |
R-CHOP | |
DA-EPOCHR | 4 (40) |
Prior auto-HCT | 0 |
Time from completion of most recent prior systemic therapy to study treatment, mo | |
<3 | 8 (80) |
3-6 | 1 (10) |
>6 | 1 (10) |
Characteristic . | MGZL (N = 10) . |
---|---|
Age, y | 35 (25-72) |
>65 | 1∗ (10) |
Male | 6 (60) |
ECOG performance status | |
0-1 | 9 (90) |
≥2 | 1 (10) |
Refractory disease† | 7 (70) |
Bulky disease >10 cm | 3 (30) |
Prior systemic cancer therapies, median (range) | 2 (1-3)‡ |
Prior therapies | 3 (30) |
R-CHOP | |
DA-EPOCHR | 4 (40) |
Prior auto-HCT | 0 |
Time from completion of most recent prior systemic therapy to study treatment, mo | |
<3 | 8 (80) |
3-6 | 1 (10) |
>6 | 1 (10) |
Values are median (range) or n (%).
ECOG, Eastern Cooperative Oncology Group; DA-EPOCHR, dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab; HCT, hematopoietic stem cell transplantation; R-CHOP, rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone.
Patient was 72 years old.
No complete remission following frontline therapy, and no complete remission/partial remission to any salvage therapy.
One patient received 2 prior regimens, but 1 regimen was unknown. This patient met the study inclusion criteria, as it was known that they had received 2 prior regimens.